Findings

What do systematic reviews say?

124 questions · 128 findings · 65 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 23 · 18%GRADE not reported 6 · 4.7%Very low 47 · 36.7%Low 35 · 27.3%Moderate 14 · 10.9%High 3 · 2.3%

Vitamin K antagonists vs low molecular weight heparin

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 0.33 [0.01, 8.1]
1 study · 439 participants
Very low
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 2 [0.18, 21.9]
1 study · 440 participants
Very low

Intervention not reported

All‐cause mortality · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…

The intervention showed no clear difference in all‐cause mortality (low certainty).

1 finding from 1 review

Chemotherapy for second‐stage human African trypanosomiasis: drugs in use 2021 · Cochrane Headline outcomes only
RR 2.22 [0.49, 10.11]
1 study · 394 participants
Low

EDTA vs placebo

All‐cause mortality · atherosclerotic cardiovascular disease

EDTA showed no clear difference in all‐cause mortality compared with placebo (low certainty).

1 finding from 1 review

Chelation therapy for atherosclerotic cardiovascular disease 2020 · Cochrane Headline outcomes only
RR 0.97 [0.73, 1.28]
2 studies · 1792 participants
Low

Intervention not reported

All‐cause mortality · people with liver metastases

The intervention showed no clear difference in all‐cause mortality (low certainty).

1 finding from 1 review

Cryotherapy for liver metastases 2019 · Cochrane Headline outcomes only
RR 0.88 [0.77, 1.02]
1 study · 123 participants
Low

Quinolone vs macrolides

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Macrolides vs tetracycline

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Quinolone vs tetracycline

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Intervention not reported

All‐cause mortality · HIV‐positive adults

The intervention showed no clear difference in all‐cause mortality (high certainty).

1 finding from 1 review

Interleukin‐2 as an adjunct to antiretroviral therapy for HIV‐positive adults 2017 · Cochrane Headline outcomes only
RR 0.97 [0.8, 1.17]
6 studies · 6565 participants
High

Extended prophylaxis vs another VTE extended prophylaxis

All‐cause mortalitye · patients with unprovoked venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Extended prophylaxis vs placebo

All‐cause mortalityg · patients with unprovoked venous thromboembolism

Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).

1 finding from 1 review

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with… 2017 · Cochrane Headline outcomes only
OR 1 [0.63, 1.57]
5 studies · 2043 participants
Moderate

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality

1 finding from 1 review

Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 425 participants
GRADE not reported

Intervention not reported

All‐cause mortality · patients with rhabdomyolysis

The intervention showed no clear difference in all‐cause mortality (low certainty).

1 finding from 1 review

Continuous renal replacement therapy (CRRT) for rhabdomyolysis 2014 · Cochrane Headline outcomes only
RR 0.17 [0.02, 1.37]
1 study · 43 participants
Low

Intervention not reported

All‐cause mortality · patients with managing pulmonary tuberculosis

The intervention showed no clear difference in all‐cause mortality (low certainty).

1 finding from 1 review

Adjunctive steroid therapy for managing pulmonary tuberculosis 2014 · Cochrane Headline outcomes only
RR 0.77 [0.51, 1.15]
18 studies · 3815 participants
Low

Intervention not reported

All‐cause mortality · participants with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Perioperative statins vs placebo or no treatment

All‐cause mortality · participants with improving outcomes during and after noncardiac vascular surgery.

Perioperative statins showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).

1 finding from 1 review

Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery 2013 · Cochrane Headline outcomes only
RR 0.73 [0.31, 1.75]
3 studies · 178 participants
Low